83,888 Shares in Aurinia Pharmaceuticals Inc $AUPH Bought by Man Group plc

Man Group plc purchased a new position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 83,888 shares of the biotechnology company’s stock, valued at approximately $1,424,000. Man Group plc owned 0.06% of Aurinia Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the company. Royal Bank of Canada raised its stake in shares of Aurinia Pharmaceuticals by 65.3% in the first quarter. Royal Bank of Canada now owns 367,661 shares of the biotechnology company’s stock worth $2,956,000 after purchasing an additional 145,179 shares during the last quarter. AQR Capital Management LLC raised its position in Aurinia Pharmaceuticals by 8.7% during the 1st quarter. AQR Capital Management LLC now owns 503,543 shares of the biotechnology company’s stock worth $4,048,000 after buying an additional 40,380 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Aurinia Pharmaceuticals by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company’s stock valued at $642,000 after acquiring an additional 3,497 shares during the period. Creative Planning lifted its stake in Aurinia Pharmaceuticals by 21.0% during the 2nd quarter. Creative Planning now owns 20,699 shares of the biotechnology company’s stock valued at $175,000 after acquiring an additional 3,594 shares during the period. Finally, Legal & General Group Plc boosted its holdings in shares of Aurinia Pharmaceuticals by 16.5% in the 2nd quarter. Legal & General Group Plc now owns 141,492 shares of the biotechnology company’s stock valued at $1,201,000 after acquiring an additional 20,027 shares during the last quarter. 36.83% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently weighed in on AUPH. Zacks Research lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 21st. Royal Bank Of Canada upped their price target on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a report on Friday, August 7th. Weiss Ratings raised Aurinia Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 26th. Bloom Burton upgraded Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Finally, Wall Street Zen lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Aurinia Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.67.

Aurinia Pharmaceuticals Price Performance

NASDAQ:AUPH opened at $16.29 on Thursday. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.42 and a quick ratio of 4.97. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of 7.11 and a beta of 1.40. The company has a 50 day moving average price of $15.87 and a 200-day moving average price of $15.53. Aurinia Pharmaceuticals Inc has a 1-year low of $10.34 and a 1-year high of $19.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.04. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. The firm had revenue of $58.57 million during the quarter, compared to analysts’ expectations of $80.45 million. Equities research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.79 EPS for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.